Biocon Inkomsten in het verleden

Verleden criteriumcontroles 4/6

Biocon is de winst gegroeid met een gemiddeld jaarlijks percentage van 9.7%, terwijl de Biotechs industrie de winst jaarlijks groeide met 9.7%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 21% per jaar. Het rendement op eigen vermogen van Biocon is 7%, en het heeft een nettomarge van 9.7%.

Belangrijke informatie

9.7%

Groei van de winst

9.4%

Groei van de winst per aandeel

Biotechs Groei van de industrie	5.1%
Inkomstengroei	21.0%
Rendement op eigen vermogen	7.0%
Nettomarge	9.7%
Laatste winstupdate	30 Sep 2024

Recente prestatie-updates uit het verleden

Biocon's (NSE:BIOCON) Promising Earnings May Rest On Soft Foundations

May 24

Recent updates

Here's What Analysts Are Forecasting For Biocon Limited (NSE:BIOCON) After Its Second-Quarter Results

Nov 02

Biocon Limited's (NSE:BIOCON) Earnings Haven't Escaped The Attention Of Investors

Jun 29

Is Biocon (NSE:BIOCON) A Risky Investment?

Jun 11

Biocon (NSE:BIOCON) Is Reducing Its Dividend To ₹0.50

Jun 11

Biocon's (NSE:BIOCON) Promising Earnings May Rest On Soft Foundations

May 24

Biocon's (NSE:BIOCON) Dividend Is Being Reduced To ₹0.50

May 23

Is Now The Time To Put Biocon (NSE:BIOCON) On Your Watchlist?

Mar 20

Biocon Limited Just Beat EPS By 240%: Here's What Analysts Think Will Happen Next

Feb 12

Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 18% Below Its Share Price

Jan 23

Shareholders Should Be Pleased With Biocon Limited's (NSE:BIOCON) Price

Jan 03

These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively

Nov 13

Estimating The Intrinsic Value Of Biocon Limited (NSE:BIOCON)

Aug 03

Biocon (NSE:BIOCON) Will Pay A Larger Dividend Than Last Year At ₹1.50

Jul 03

Is Biocon (NSE:BIOCON) Using Too Much Debt?

Jul 02

Biocon's (NSE:BIOCON) Dividend Will Be Increased To ₹1.50

May 26

Estimating The Fair Value Of Biocon Limited (NSE:BIOCON)

Mar 28

Here's Why Biocon (NSE:BIOCON) Can Manage Its Debt Responsibly

Feb 26

Biocon Limited (NSE:BIOCON) Shares Could Be 24% Above Their Intrinsic Value Estimate

Dec 17

Is There An Opportunity With Biocon Limited's (NSE:BIOCON) 46% Undervaluation?

Sep 05

Is Biocon (NSE:BIOCON) Using Too Much Debt?

Jul 13

Biocon Limited (NSE:BIOCON) Shares Could Be 20% Below Their Intrinsic Value Estimate

May 26

Opbrengsten en kosten

Hoe Biocon geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NSEI:BIOCON Opbrengsten, kosten en inkomsten (INR Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	148,941	14,392	31,958	-1,515
30 Jun 24	147,660	15,808	30,286	-1,110
31 Mar 24	147,557	10,225	28,525	-838
31 Dec 23	146,125	12,002	26,439	-119
30 Sep 23	135,999	4,984	24,819	-1,238
30 Jun 23	124,573	4,197	23,998	-2,156
31 Mar 23	111,742	4,627	23,331	-3,922
31 Dec 22	98,091	3,881	22,558	-5,606
30 Sep 22	90,422	6,170	21,920	-5,825
30 Jun 22	85,629	7,084	21,305	-5,768
31 Mar 22	81,840	6,484	20,539	-4,764
31 Dec 21	75,800	6,727	20,252	-4,050
30 Sep 21	72,632	6,542	19,935	-3,581
30 Jun 21	71,726	6,852	19,466	-3,530
31 Mar 21	71,431	7,405	17,485	-3,507
31 Dec 20	68,913	5,996	16,778	-3,607
30 Sep 20	67,571	6,362	15,906	-3,596
30 Jun 20	65,796	6,870	15,120	-3,568
31 Mar 20	63,005	7,771	16,545	-3,458
31 Dec 19	63,150	8,385	13,910	-3,001
30 Sep 19	61,077	8,529	13,093	-2,746
30 Jun 19	58,565	9,919	12,449	-2,757
31 Mar 19	55,144	9,053	11,653	-2,699
31 Dec 18	51,551	8,220	11,087	-2,421
30 Sep 18	46,722	6,967	10,496	-2,449
30 Jun 18	43,198	4,108	9,862	-1,993
31 Mar 18	41,234	3,724	9,311	-1,747
31 Dec 17	38,792	3,695	8,708	-1,522
30 Sep 17	38,589	4,489	8,297	-1,257
30 Jun 17	38,361	5,268	7,846	-1,324
31 Mar 17	38,911	6,121	7,510	-1,283
31 Dec 16	40,487	11,633	7,458	-1,472
30 Sep 16	38,110	10,961	7,038	-1,468
30 Jun 16	36,539	9,388	6,665	-1,378
31 Mar 16	33,474	5,504	6,128	-1,320
31 Dec 15	32,997	7,367	8,595	-202
30 Sep 15	32,325	7,247	8,366	-196
30 Jun 15	31,528	5,207	8,223	-272
31 Mar 15	30,898	4,974	5,371	-1,321
31 Dec 14	29,807	4,091	7,565	-386
30 Sep 14	29,168	4,231	7,360	-561
30 Jun 14	29,014	4,232	7,137	-585
31 Mar 14	28,773	4,138	7,035	-642
31 Dec 13	28,180	5,493	6,636	47

Kwaliteitswinsten: BIOCON heeft een grote eenmalige winst van ₹13.3B wat gevolgen heeft voor de financiële resultaten van de laatste 12 maanden tot 30th September, 2024.

Groeiende winstmarge: De huidige netto winstmarges (9.7%) BIOCON } zijn hoger dan vorig jaar (3.7%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van BIOCON is de afgelopen 5 jaar met 9.7% per jaar gegroeid.

Versnelling van de groei: De winstgroei van BIOCON over het afgelopen jaar ( 188.8% ) overtreft het 5-jarig gemiddelde ( 9.7% per jaar).

Winst versus industrie: De winstgroei BIOCON over het afgelopen jaar ( 188.8% ) overtrof de Biotechs -sector 5.5%.

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 7% ) van BIOCON wordt als laag beschouwd.

Biocon Inkomsten in het verleden

Verleden criteriumcontroles 4/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Second quarter 2025 earnings released: ₹0.13 loss per share (vs ₹1.05 profit in 2Q 2024)

Biocon Limited to Report Q2, 2025 Results on Oct 30, 2024

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Biocon Limited to Report Q1, 2025 Results on Aug 08, 2024

Biocon's (NSE:BIOCON) Promising Earnings May Rest On Soft Foundations

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Recent updates

Here's What Analysts Are Forecasting For Biocon Limited (NSE:BIOCON) After Its Second-Quarter Results

New major risk - Financial position

Why Investors Shouldn't Be Surprised By Biocon Limited's (NSE:BIOCON) Low P/E

Second quarter 2025 earnings released: ₹0.13 loss per share (vs ₹1.05 profit in 2Q 2024)

Do Biocon's (NSE:BIOCON) Earnings Warrant Your Attention?

Biocon Limited to Report Q2, 2025 Results on Oct 30, 2024

These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively

High number of new directors

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Biocon Limited to Report Q1, 2025 Results on Aug 08, 2024

Biocon Limited's (NSE:BIOCON) Earnings Haven't Escaped The Attention Of Investors

Upcoming dividend of ₹0.50 per share

Biocon Limited Announces Appointment of Mukesh Kamath, Head - Business Finance R&D, as the Interim Chief Financial Officer

Investor sentiment improves as stock rises 18%

Is Biocon (NSE:BIOCON) A Risky Investment?

Biocon (NSE:BIOCON) Is Reducing Its Dividend To ₹0.50

Biocon's (NSE:BIOCON) Promising Earnings May Rest On Soft Foundations

Biocon's (NSE:BIOCON) Dividend Is Being Reduced To ₹0.50

New minor risk - Earnings quality

Dividend of ₹0.50 announced

Biocon Limited, Annual General Meeting, Aug 09, 2024

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Insider recently sold ₹5.3m worth of stock

Is Now The Time To Put Biocon (NSE:BIOCON) On Your Watchlist?

Biocon Limited Accepts Resignation of Indranil Sen as Chief Financial Officer

Insider recently sold ₹3.3m worth of stock

Insider recently sold ₹1.1m worth of stock

Biocon Limited Just Beat EPS By 240%: Here's What Analysts Think Will Happen Next

Biocon Limited Announces Nehal Vora Resigns as Commercial Head, Effective March 31, 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 18% Below Its Share Price

Investor sentiment improves as stock rises 17%

Shareholders Should Be Pleased With Biocon Limited's (NSE:BIOCON) Price

Insider recently sold ₹1.8m worth of stock

Biocon Limited Announces the Resignation of Prasad Deshpande as Head SCM and Central Engineering, Senior Management Personnel, Effective January 16, 2024

Biocon Limited Appoints Nicholas Robert Haggar as an Independent Director

These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Biocon Limited Announces Management Changes

Insider recently sold ₹13m worth of stock

Group Chief Information Officer recently sold ₹3.2m worth of stock

Biocon Limited Appoints Peter Bains as Biocon Group Chief Executive Officer

Insider recently sold ₹1.6m worth of stock

Consensus EPS estimates fall by 16%

Biocon Limited Approves Appointment of Ms. Rekha Mehrotra Menon as an Independent Director

Estimating The Intrinsic Value Of Biocon Limited (NSE:BIOCON)

Biocon Limited Announces Cessation of Vijay Kumar Kuchroo as a Director

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Insider selling

Biocon (NSE:BIOCON) Will Pay A Larger Dividend Than Last Year At ₹1.50

Is Biocon (NSE:BIOCON) Using Too Much Debt?

Upcoming dividend of ₹1.50 per share at 0.6% yield

Insider recently sold ₹5.3m worth of stock

Biocon's (NSE:BIOCON) Dividend Will Be Increased To ₹1.50

Biocon Limited, Annual General Meeting, Aug 11, 2023

Biocon Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023, Payable on or Before September 8, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates increase by 12%

Insider recently sold ₹2.3m worth of stock

Estimating The Fair Value Of Biocon Limited (NSE:BIOCON)

Insider recently sold ₹1.1m worth of stock

Here's Why Biocon (NSE:BIOCON) Can Manage Its Debt Responsibly

Consensus EPS estimates fall by 17%

Price target decreased by 7.4% to ₹316

Biocon Plans to Sell Stake in Biologics Arm to Pare Debt

Third quarter 2023 earnings released: ₹0.35 loss per share (vs ₹1.57 profit in 3Q 2022)

Biocon Limited to Report Q2, 2024 Results on Nov 06, 2023

Consensus forecasts updated

Biocon Limited to Report Q3, 2023 Results on Feb 14, 2023